Cargando…
On-treatment measurements of circulating tumor DNA during FOLFOX therapy in patients with colorectal cancer
We addressed a significant unknown feature of circulating tumor DNA (ctDNA), i.e., how ctDNA levels change during chemotherapy, by serially monitoring ctDNA in patients with colorectal cancer during the 48-h application of FOLFOX. Surprisingly, we did not observe a spike in ctDNA as a sign of a resp...
Autores principales: | Moser, Tina, Waldispuehl-Geigl, Julie, Belic, Jelena, Weber, Sabrina, Zhou, Qing, Hasenleithner, Samantha O., Graf, Ricarda, Terzic, Jasmin Alia, Posch, Florian, Sill, Heinz, Lax, Sigurd, Kashofer, Karl, Hoefler, Gerald, Schoellnast, Helmut, Heitzer, Ellen, Geigl, Jochen B., Bauernhofer, Thomas, Speicher, Michael R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7666126/ https://www.ncbi.nlm.nih.gov/pubmed/33299124 http://dx.doi.org/10.1038/s41698-020-00134-3 |
Ejemplares similares
-
Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone or enzalutamide
por: Belic, Jelena, et al.
Publicado: (2018) -
Whole-genome plasma sequencing reveals focal amplifications as a driving force in metastatic prostate cancer
por: Ulz, Peter, et al.
Publicado: (2016) -
Changes in Colorectal Carcinoma Genomes under Anti-EGFR Therapy Identified by Whole-Genome Plasma DNA Sequencing
por: Mohan, Sumitra, et al.
Publicado: (2014) -
Establishment of tumor-specific copy number alterations from plasma DNA of patients with cancer
por: Heitzer, Ellen, et al.
Publicado: (2013) -
Cell-free DNA analysis reveals POLR1D-mediated resistance to bevacizumab in colorectal cancer
por: Zhou, Qing, et al.
Publicado: (2020)